TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CAMBRIDGE, Mass., Oct. 14, 2016 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the European Society of Gene & Cell Therapy Congress (ESGCT) in Florence, Italy from October 18-21, 2016. Abstracts will be available online at esgct.eu on October 17, 2016.
“The data being presented at ESGCT show Intellia’s continued progress with its CRISPR/Cas9 platform,” said John Leonard, M.D., chief medical officer, Intellia Therapeutics. “These findings are important as we learn more about CRISPR/Cas9 and move toward clinical studies in patients.”
The following posters have been scheduled for presentation:
| Number | Poster Title | Presenter | Time |
| #283 | Efficient assessment of CRISPR/Cas9 off-target activity using a background double-strand break model | Reynald Lescarbeau, Ph.D. Computational Scientist, Bioinformatics | October 19, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #280 | Robust in vivo gene editing in mouse hepatocytes with systemic lipid nanoparticle delivery of CRISPR/Cas9 components | David Morrissey, Ph.D. Chief Technology Officer | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #320 | DNA repair events after cleavage by CRISPR/Cas9 are not random | Walter Strapps, Ph.D. Senior Director, Biology | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #310 | Translating CRISPR/Cas9 genome editing into therapeutics | Tom Barnes, Ph.D. Chief Scientific Officer | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 224-804-4462 [email protected] Investor Contacts: John Graziano Trout Group +1 646-378-2942 [email protected] Chad Rubin Trout Group +1 646-378-2947 [email protected]
